NRG Therapeutics’ preclinical report invites readers to examine lab and mechanistic data for a novel ALS drug candidate and its next-stage plans.
Key Takeaways
- NRG5051 reduced plasma neurofilament light in TDP43 mouse models, indicating neuroprotection
- Drug acts via an NLRX1‑mediated mechanism linked to mitochondrial permeability transition pore regulation
- Randomized double‑blind Phase 1 in healthy volunteers is underway with ALS patient dosing scheduled later in 2026